Shoulder Innovations reported 3Q25 orthopedic sales of $11.8 million, up 57.7% compared to the third quarter of 2024. For the first nine months of the year, the company generated $32.9 million in orthopedic sales, up 43.7% compared to the prior period.
During the quarter, the company sold 1,584 implant systems, a 53% increase over the second quarter. Shoulder Innovations also expanded its product line up with the full commercial launch of the InSet 70 for its I-Series humeral stem product line.
It also received FDA 510(k) clearance for expanding the I-Series humeral stem product line to include certain fracture indications.
Shoulder Innovations now expects full-year revenue in the range of $45 million to $46 million, representing growth between 33% and 39%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment
3Q25
3Q24
$ Chg
% Chg
Extremity Joint Replacement
$11.8
$7.5
$4.3
57.7%
Segment
9mo25
9mo24
$ Chg
% Chg
Extremity Joint Replacement
$32.9
$22.9
$10.0
43.7%
Company Earnings
Amt
% of Sales
Sales
$11.8
Cost of Sales
$2.8
23.8%
Sales and Marketing
$15.1
128.2%
R & D
$1.5
13%
Other
$1.1
9.6%
Net Earnings
($8.8)
(74.6%)
Shoulder Innovations reported 3Q25 orthopedic sales of $11.8 million, up 57.7% compared to the third quarter of 2024. For the first nine months of the year, the company generated $32.9 million in orthopedic sales, up 43.7% compared to the prior period.
During the quarter, the company sold 1,584 implant systems, a 53% increase over the...
Shoulder Innovations reported 3Q25 orthopedic sales of $11.8 million, up 57.7% compared to the third quarter of 2024. For the first nine months of the year, the company generated $32.9 million in orthopedic sales, up 43.7% compared to the prior period.
During the quarter, the company sold 1,584 implant systems, a 53% increase over the second quarter. Shoulder Innovations also expanded its product line up with the full commercial launch of the InSet 70 for its I-Series humeral stem product line.
It also received FDA 510(k) clearance for expanding the I-Series humeral stem product line to include certain fracture indications.
Shoulder Innovations now expects full-year revenue in the range of $45 million to $46 million, representing growth between 33% and 39%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment
3Q25
3Q24
$ Chg
% Chg
Extremity Joint Replacement
$11.8
$7.5
$4.3
57.7%
Segment
9mo25
9mo24
$ Chg
% Chg
Extremity Joint Replacement
$32.9
$22.9
$10.0
43.7%
Company Earnings
Amt
% of Sales
Sales
$11.8
Cost of Sales
$2.8
23.8%
Sales and Marketing
$15.1
128.2%
R & D
$1.5
13%
Other
$1.1
9.6%
Net Earnings
($8.8)
(74.6%)
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
